Get the Stockscreener App
9.78
2.62%
0.25
After Hours:
9.78
Delcath Systems Inc stock is traded at $9.78, with a volume of 674.50K.
It is up +2.62% in the last 24 hours and down -4.02% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$9.53
Open:
$9.44
24h Volume:
674.50K
Relative Volume:
1.22
Market Cap:
$339.37M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-3.4681
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
+5.05%
1M Performance:
-4.02%
6M Performance:
-5.32%
1Y Performance:
-37.07%
1-Day Range:
$9.40
$9.855
1-Week Range:
$9.24
$9.855
52-Week Range:
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
9.78 | 330.69M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
112.21 | 195.08B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
380.23 | 142.61B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
96.86 | 125.10B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
74.58 | 112.29B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.78 | 45.80B | 6.07B | 1.06B | 799.60M | 1.8527 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Chipmakers Recap: Can IONQ lead its sector in growthMarket Growth Summary & Daily Stock Trend Reports - baoquankhu1.vn
Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a Potential 134% Upside in the Healthcare Sector - DirectorsTalk Interviews
Will Delcath Systems Inc. stock recover faster than peersTrade Analysis Summary & Daily Entry Point Trade Alerts - mfd.ru
Is Delcath Systems Inc. stock a safe investment in uncertain marketsMarket Risk Report & Fast Exit/Entry Strategy Plans - mfd.ru
Ocular melanoma Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Delcath System, Aura Biosciences, Seagen, IDEAYA, Ascentage Pharma - Barchart.com
Clear Street raises Delcath Systems, Inc. (DCTH) target to $29, maintains buy rating - MSN
Technical Reactions to DCTH Trends in Macro Strategies - Stock Traders Daily
Does The Market Have A Low Tolerance For Delcath Systems, Inc.'s (NASDAQ:DCTH) Mixed Fundamentals? - Yahoo Finance
Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a Compelling 144.88% Upside Potential - DirectorsTalk Interviews
Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call - BioSpace
Is Delcath Systems Inc. a strong candidate for buy and hold2025 Support & Resistance & Daily Stock Trend Reports - mfd.ru
Clear Street Raises Delcath Systems, Inc. (DCTH) Target to $29, Maintains Buy Rating - Insider Monkey
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
Fund Flows: Is Delcath Systems Inc subject to activist investor interestWeekly Investment Report & Risk Controlled Swing Alerts - baoquankhu1.vn
Trading the Move, Not the Narrative: (DCTH) Edition - Stock Traders Daily
Canaccord Genuity Sticks to Their Buy Rating for Delcath Systems (DCTH) - The Globe and Mail
The Robot Revolution Is Here: Stocks to Consider from Tesla, Hyundai, and Others. - Intellectia AI
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Delcath Systems Faces Valuation Shift Amidst Mixed Financial Indicators and Growth Trends - Markets Mojo
Aug Gainers: Can Delcath Systems Inc continue delivering strong returns2025 Year in Review & Capital Efficient Trade Techniques - baoquankhu1.vn
Can Delcath Systems Inc. continue delivering strong returnsJuly 2025 Closing Moves & Safe Entry Momentum Tips - mfd.ru
Liver cancer-focused Delcath joins BTIG MedTech, digital health conference - Stock Titan
Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Yahoo Finance
(DCTH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Analysis Recap: Is CYCCP forming a double bottomMarket Growth Report & Real-Time Market Sentiment Reports - baoquankhu1.vn
Retail Surge: Can Delcath Systems Inc continue delivering strong returnsQuarterly Portfolio Review & Consistent Return Investment Signals - baoquankhu1.vn
Returns On Capital Are Showing Encouraging Signs At Delcath Systems (NASDAQ:DCTH) - Yahoo Finance
Delcath Systems, Inc. (DCTH) Stock Analysis: A 103% Upside Potential In Medical Devices - DirectorsTalk Interviews
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 21, 2026 - BioSpace
Delcath Systems, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Is Delcath Systems Inc backed by strong institutional buyingLong Setup & Daily Growth Stock Investment Tips - baoquankhu1.vn
UTSW first in Texas to offer novel treatment for rare eye cancer that spreads to the liver : Newsroom - UT Southwestern
Market Catalysts: Is ODYS forming a bullish divergenceEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Price-Driven Insight from (DCTH) for Rule-Based Strategy - Stock Traders Daily
Delcath Systems expects FY revenue of $85.2 million - MSN
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems Reports Strong Preliminary 2025 Results - TipRanks
NY-based Delcath Systems expects Q4 2025 revenue to hit USD 20.7M - Medical Buyer
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2025 Earnings Call Transcript - MSN
EBITDA per share of Delcath Systems, Inc. – DUS:DV3R - TradingView — Track All Markets
Delcath reports $85.2 million in 2025 revenue, strong cash position By Investing.com - Investing.com Nigeria
Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
DCTH FinancialsIncome Statement - Quiver Quantitative
DCTH: HC Wainwright Reiterates Buy Rating with $30 Price Target - GuruFocus
HC Wainwright Reaffirms Buy Rating for Delcath Systems (NASDAQ:DCTH) - MarketBeat
Delcath Systems, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 - MarketScreener
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Delcath Systems Inc Stock (DCTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER |
Nov 11 '25 |
Buy |
8.53 |
11,500 |
98,049 |
330,834 |
| Vukovic Vojo | CHIEF MEDICAL OFFICER |
Jun 12 '25 |
Option Exercise |
4.78 |
42,000 |
200,760 |
168,882 |
0.50%
1.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):